Foralumab

Dementia

Brigham and Women's Hospitalmonoclonal_antibodyPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

39 Active assets in the Dementia cohort.

Asset / Sponsor	Phase	Rating
Sra-333 The University of Texas Health Science Center at San Antonio	Phase 4	BBB
Risperdal Hannover Medical School	Phase 4	BBB
CITALOPRAM Hannover Medical School	Phase 4	BBB
Namenda Zealand University Hospital	Phase 4	BB
Galantamine Hydrobromide Janssen Pharmaceutica N.V., Belgium	Phase 3	BB

View all 50 →

Same molecule, other indications

Foralumab is also rated in:

Non-Active Secondary Progressive Multiple SclerosisDormant

B

Indicative ·

60 / 100

secondary progressive multiple sclerosisDormant

CCC

Indicative ·

53 / 100

Alzheimers DiseaseDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.